Study identifies eosinophil levels as key to predicting gastrointestinal lesions in eosinophilic granulomatosis, offering a ...

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). According to GlobalData, Phase II drugs for ...

Wegener’s granulomatosis (WG) is a systemic inflammatory disease whose histopathologic features often include necrosis, granuloma formation, and vasculitis of small-to-medium-sized vessels. We report ...

Wegener's granulomatosis/granulomatosis with polyangiitis is a fatal disease if left untreated, and the natural history is for only 50% of patients to survive 5 ...

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of vasculitis, meaning it causes inflammation in small and medium sized blood vessels, which can result in damage to organs ...

Wegener's granulomatosis (newly renamed granulomatosis with polyangiitis [WG/GPA]) is a granulomatous autoimmune inflammatory disorder of unknown etiology that is associated with anti-neutrophil ...